VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

A. Your doctor was correct that depression and suicidal thoughts do not appear in the official prescribing information for evolocumab (Repatha) or a similar drug, alirocumab (Praluent). Both are ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

They agreed to charge the U.S. government no more for new drugs than the prices paid by other well-off countries. The agreements will allow state Medicaid programs to access lower prices from the nine ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

Primary prevention targets individuals with ASCVD risk factors, while secondary prevention focuses on those with prior cardiovascular events, requiring more intensive management. Statin intolerance ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

(CNN) — For some people with high cholesterol, making lifestyle changes and taking routine statin medications may not be sufficient to help them reach their target cholesterol levels. For these ...

NEW ORLEANS, LA—A PCSK9 inhibitor used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo ...

Findings that evolocumab significantly reduced the risk of major adverse CV events in adults at high CV risk without prior heart attack or stroke vs placebo. Topline data were announced from a phase 3 ...